Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD

BACKGROUND: The oral selective phosphodiesterase-4 inhibitor roflumilast (ROF) reduces exacerbations in patients with severe COPD. Adverse events (AEs) can cause early ROF discontinuation. Alternative dosing strategies may help patients continue their therapy. METHODS: In this multicenter, double-bl...

Descripción completa

Detalles Bibliográficos
Autores principales: Watz, Henrik, Bagul, Nitin, Rabe, Klaus F, Rennard, Stephen, Alagappan, Vijay KT, Román, Jonas, Facius, Axel, Calverley, Peter MA
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846760/
https://www.ncbi.nlm.nih.gov/pubmed/29563781
http://dx.doi.org/10.2147/COPD.S154012

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846760/
https://www.ncbi.nlm.nih.gov/pubmed/29563781
http://dx.doi.org/10.2147/COPD.S154012

Ejemplares similares